Mylan and Pfizer Names Viatris as the New Company for Mylan-Upjohn’s Combination

 Mylan and Pfizer Names Viatris as the New Company for Mylan-Upjohn’s Combination

Mylan and Pfizer Reports Viatris as the New Company Name for Mylan-Upjohn’s Collaboration

Shots:

  • The name Viatris symbolizes the new company’s goal of providing a path- “VIA’ —to three—”TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs and being a trusted partner for the healthcare community worldwide
  • Viatris to bring together Upjohn’s position in China and emerging markets with Mylan’s presence in the US and Europe, allowing the new company to have expanded geographic reach for its portfolio and future pipeline
  • The new name, Viatris will be effective upon closing of the combination, which is expected to occur in H2’20. The two companies will continue to operate as independent, separate organizations until close

Click here to­ read full press release/ article | Ref: Mylan | Image: Business line

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post